Comparative efficacy of Helicobacter pylori eradication therapy between tegoprazan‐based concomitant and bismuth quadruple therapies: A real‐world evidence

相伴的 医学 幽门螺杆菌 内科学 不利影响 克拉霉素 胃肠病学 质子抑制剂泵 置信区间 联合疗法 外科 材料科学 冶金
作者
Yoon Suk Jung,Byung Wook Jung,Chan Hyuk Park
出处
期刊:Journal of Gastroenterology and Hepatology [Wiley]
被引量:1
标识
DOI:10.1111/jgh.16798
摘要

Abstract Background and Aim Tegoprazan, a potassium‐competitive acid blocker, can be used as a substitute for proton pump inhibitors in Helicobacter pylori eradication therapy; some studies have reported improved efficacy. In Korea, where clarithromycin resistance rates are high, we aimed to compare the efficacies of tegoprazan‐based concomitant and bismuth quadruple therapies. Methods We retrospectively analyzed data from patients with H. pylori infection who received either 10‐day tegoprazan‐based concomitant therapy or 14‐day tegoprazan‐based bismuth quadruple therapy as first‐line treatment. The primary outcome was H. pylori eradication rate, with secondary outcomes including adverse events and insufficient medication rates. Results Among the 1082 patients included in the study, 620 and 462 were treated with tegoprazan‐based concomitant and bismuth quadruple therapies, respectively. Intention‐to‐treat analysis demonstrated no difference in eradication rates between the tegoprazan‐based concomitant and bismuth quadruple therapy groups (74.7% [95% confidence interval—CI, 71.1–78.0%] vs 74.7% [95% CI, 70.6–78.5%], P = 0.999). Per‐protocol analysis also showed similar eradication rates between the two groups (88.0% [95% CI, 85.0–90.6%] vs 89.7% [95% CI, 86.3–92.5%], P = 0.424). The overall adverse event rates (49.6% vs 39.2%, P = 0.001) and insufficient medication rates (4.8% vs 2.4%, P = 0.036) were higher in the bismuth quadruple therapy group than in the concomitant therapy group. Conclusions The eradication rates of tegoprazan‐based 10‐day concomitant therapy and 14‐day bismuth quadruple therapy were comparable. However, because of its shorter treatment duration, better medical adherence, and lower incidence of adverse events, tegoprazan‐based concomitant therapy may be preferable in regions with high rates of clarithromycin and metronidazole resistance.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小马甲应助小周采纳,获得10
刚刚
tttt完成签到 ,获得积分10
刚刚
jh完成签到,获得积分10
1秒前
沉默安波发布了新的文献求助10
1秒前
zzf发布了新的文献求助10
1秒前
栖木木完成签到 ,获得积分10
1秒前
τ涛发布了新的文献求助10
1秒前
ZH发布了新的文献求助10
1秒前
benben055发布了新的文献求助10
2秒前
2秒前
所所应助暗栀采纳,获得10
2秒前
科研搬运工完成签到,获得积分0
2秒前
乐乐应助1nv1采纳,获得10
3秒前
WTH完成签到,获得积分10
3秒前
3秒前
master完成签到,获得积分10
3秒前
大洁完成签到,获得积分10
3秒前
4秒前
4秒前
结实寄柔完成签到,获得积分10
5秒前
昏睡的纸鹤完成签到,获得积分10
5秒前
5秒前
研友_LXOrO8完成签到,获得积分10
5秒前
无妄生欢完成签到,获得积分10
6秒前
6秒前
6秒前
小汪同学完成签到,获得积分10
6秒前
6秒前
111完成签到,获得积分10
7秒前
8秒前
欢呼妙菱发布了新的文献求助10
8秒前
王俊凯完成签到 ,获得积分10
8秒前
可可发布了新的文献求助10
8秒前
爱学习的GGbond完成签到,获得积分10
8秒前
王院士发布了新的文献求助10
9秒前
花痴的翠容完成签到,获得积分10
9秒前
nanyuan123完成签到,获得积分10
9秒前
9秒前
李爱国应助阿威啊威采纳,获得10
9秒前
彭于彦祖应助djbj2022采纳,获得30
10秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3969335
求助须知:如何正确求助?哪些是违规求助? 3514162
关于积分的说明 11172430
捐赠科研通 3249456
什么是DOI,文献DOI怎么找? 1794853
邀请新用户注册赠送积分活动 875437
科研通“疑难数据库(出版商)”最低求助积分说明 804809